• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).

作者信息

Abedi Farshad, Rezaee Ramin, Karimi Gholamreza

机构信息

Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran.

Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Pharmacol Res. 2020 Jun;156:104808. doi: 10.1016/j.phrs.2020.104808. Epub 2020 Apr 10.

DOI:10.1016/j.phrs.2020.104808
PMID:32283223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7195000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e4e/7195000/81e8bf0499a7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e4e/7195000/81e8bf0499a7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e4e/7195000/81e8bf0499a7/gr1_lrg.jpg

相似文献

1
Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).Rho激酶抑制剂对严重急性呼吸综合征冠状病毒2（COVID-19）治疗作用的合理性。
Pharmacol Res. 2020 Jun;156:104808. doi: 10.1016/j.phrs.2020.104808. Epub 2020 Apr 10.
2
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
3
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?白细胞介素-17能否成为治疗和/或管理新型冠状病毒肺炎相关呼吸综合征的新治疗靶点？
Pharmacol Res. 2020 Jun;156:104791. doi: 10.1016/j.phrs.2020.104791. Epub 2020 Apr 14.
4
Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.与白细胞介素-6升高相关的血管微血栓形成。在接受托珠单抗治疗的COVID-19患者中出现的严重急性呼吸窘迫综合征。
Adv Respir Med. 2020;88(5):468-469. doi: 10.5603/ARM.a2020.0123.
5
Calcineurin inhibitors revisited: A new paradigm for COVID-19?钙调磷酸酶抑制剂再探讨：COVID-19 的新范式？
Braz J Infect Dis. 2020 Jul-Aug;24(4):365-367. doi: 10.1016/j.bjid.2020.06.005. Epub 2020 Jun 27.
6
Teicoplanin: an alternative drug for the treatment of COVID-19?替考拉宁：治疗 COVID-19 的一种替代药物？
Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.
7
Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.严重急性呼吸综合征冠状病毒2对干扰素表达的弱诱导作用支持了干扰素λ治疗早期2019冠状病毒病的临床试验。
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
8
Imatinib for COVID-19: A case report.伊马替尼治疗新型冠状病毒肺炎：一例病例报告。
Clin Immunol. 2020 Sep;218:108518. doi: 10.1016/j.clim.2020.108518. Epub 2020 Jun 27.
9
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.将抗癌药物重新用于 COVID-19 引起的炎症、免疫功能障碍和凝血障碍。
Br J Cancer. 2020 Sep;123(5):694-697. doi: 10.1038/s41416-020-0948-x. Epub 2020 Jun 22.
10
Misguided drug advice for COVID-19.针对新冠病毒病的错误用药建议。
Science. 2020 Mar 27;367(6485):1434. doi: 10.1126/science.abb8034. Epub 2020 Mar 20.

引用本文的文献

1
Remdesivir: treatment of COVID-19 in special populations.瑞德西韦：特殊人群中新型冠状病毒肺炎的治疗
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3829-3855. doi: 10.1007/s00210-023-02927-2. Epub 2024 Jan 5.
2
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy.新冠病毒感染后病症的血管机制：Rho 激酶是一种新的治疗靶点。
Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):371-386. doi: 10.1093/ehjcvp/pvad025.
3
A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections.

本文引用的文献

1
Acute lung injury: The therapeutic role of Rho kinase inhibitors.急性肺损伤：Rho 激酶抑制剂的治疗作用。
Pharmacol Res. 2020 May;155:104736. doi: 10.1016/j.phrs.2020.104736. Epub 2020 Mar 2.
2
Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.新型冠状病毒（2019-nCoV/SARS-CoV-2）受体ACE2在不同人群中的比较遗传分析。
Cell Discov. 2020 Feb 24;6:11. doi: 10.1038/s41421-020-0147-1. eCollection 2020.
3
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.
一项单细胞图谱揭示了新冠病毒和艾滋病毒-1感染中共同的和独特的免疫反应及代谢特征。
Front Genet. 2023 Mar 13;14:1105673. doi: 10.3389/fgene.2023.1105673. eCollection 2023.
4
Inhibition of IL-6 signaling prevents serum-induced umbilical cord artery dysfunction from patients with severe COVID-19.抑制 IL-6 信号通路可预防重症 COVID-19 患者血清诱导的脐带动脉功能障碍。
Am J Physiol Regul Integr Comp Physiol. 2023 Apr 1;324(4):R435-R445. doi: 10.1152/ajpregu.00154.2022. Epub 2023 Feb 3.
5
Extracellular vesicle proteomics and phosphoproteomics identify pathways for increased risk in patients hospitalized with COVID-19 and type 2 diabetes mellitus.细胞外囊泡蛋白质组学和磷酸化蛋白质组学鉴定 COVID-19 住院患者和 2 型糖尿病患者风险增加的途径。
Diabetes Res Clin Pract. 2023 Mar;197:110565. doi: 10.1016/j.diabres.2023.110565. Epub 2023 Feb 1.
6
Severe COVID-19-A Review of Suggested Mechanisms Based on the Role of Extracellular Matrix Stiffness.严重 COVID-19-基于细胞外基质硬度作用的建议机制综述。
Int J Mol Sci. 2023 Jan 7;24(2):1187. doi: 10.3390/ijms24021187.
7
Roles of the ACE/Ang II/AT1R pathway, cytokine release, and alteration of tight junctions in COVID-19 pathogenesis.ACE/Ang II/AT1R 通路、细胞因子释放以及紧密连接改变在 COVID-19 发病机制中的作用。
Tissue Barriers. 2023 Apr 3;11(2):2090792. doi: 10.1080/21688370.2022.2090792. Epub 2022 Jun 21.
8
A network biology approach to identify crucial host targets for COVID-19.一种网络生物学方法，用于鉴定 COVID-19 的关键宿主靶标。
Methods. 2022 Jul;203:108-115. doi: 10.1016/j.ymeth.2022.03.016. Epub 2022 Mar 29.
9
An in silico analysis identifies drugs potentially modulating the cytokine storm triggered by SARS-CoV-2 infection.计算机分析鉴定出可能调节由 SARS-CoV-2 感染引发的细胞因子风暴的药物。
Sci Rep. 2022 Jan 31;12(1):1626. doi: 10.1038/s41598-022-05597-x.
10
Identification of potentially anti-COVID-19 active drugs using the connectivity MAP.利用连接图识别具有抗 COVID-19 活性的潜在药物。
PLoS One. 2022 Jan 27;17(1):e0262751. doi: 10.1371/journal.pone.0262751. eCollection 2022.
血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
4
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
5
RhoA-Rho associated kinase signaling leads to renin-angiotensin system imbalance and angiotensin converting enzyme 2 has a protective role in acute pulmonary embolism.RhoA-Rho 相关激酶信号通路导致肾素-血管紧张素系统失衡，血管紧张素转换酶 2 在急性肺栓塞中起保护作用。
Thromb Res. 2019 Apr;176:85-94. doi: 10.1016/j.thromres.2019.02.016. Epub 2019 Feb 15.
6
Molecular mechanisms of severe acute respiratory syndrome (SARS).严重急性呼吸综合征（SARS）的分子机制
Respir Res. 2005 Jan 20;6(1):8. doi: 10.1186/1465-9921-6-8.